RIBOMIC Inc. (Tokyo Stock Exchange: 4591) is a Tokyo-based biotechnology company specializing in RNA therapeutics and RNA aptamer technology. Founded in 2005, the company focuses on developing novel nucleic acid-based therapeutics using its proprietary RNA aptamer platform, positioning itself as a leader in the emerging RNA aptamer therapeutics field in Japan[1].
RIBOMIC operates as a clinical-stage biotechnology company with a focus on developing RNA aptamers—single-stranded DNA or RNA molecules that can bind specifically to target proteins—for the treatment of ocular diseases and central nervous system disorders. The company's proprietary platform enables the systematic selection and optimization of high-affinity RNA aptamers with drug-like properties.
| Attribute | Details |
|---|---|
| Founded | 2005 |
| Headquarters | Tokyo, Japan |
| Stock Symbol | TSE: 4591 (Standard Market) |
| Market Cap | ¥3-5 billion (~$20-35M USD) |
| Employees | ~50 |
| CEO | Dr. Tomohiro Kanda |
| Focus Areas | RNA aptamers, ocular diseases, CNS disorders |
RIBOMIC was established in 2005 as a spinout from academic research in RNA aptamer technology:
2005: Company founded in Tokyo, based on SELEX (Systematic Evolution of Ligands by EXponential enrichment) technology developed at Japanese academic institutions.
2008: Established proprietary RNA aptamer selection platform with improved affinity and stability characteristics.
2010: RBM-007 program initiated for age-related macular degeneration (AMD).
2012: Listed on the Tokyo Stock Exchange (TSE Mothers market), raising capital for clinical development.
2014: Moved to TSE Standard market from Mothers market, reflecting increased market capitalization.
2016: Initiated Phase 1/2 clinical trial for RBM-007 in wet AMD in Japan.
2018: Completed Phase 1/2 study demonstrating safety and preliminary efficacy.
2020: RBM-007 received orphan drug designation from Japanese regulatory authorities.
2021: Expanded clinical development to additional ocular indications.
2022: Strategic partnership discussions with major pharmaceutical companies for RBM-007.
2023: Continued Phase 2 development of RBM-007; exploration of CNS applications.
RIBOMIC's core technology is the RNA aptamer platform—a sophisticated drug discovery method that enables the systematic selection and development of RNA molecules capable of binding specifically to target proteins[2].
Advantages over antibodies:
| Feature | RNA Aptamers | Antibodies |
|---|---|---|
| Size | 5-15 kDa | 150 kDa |
| Manufacturing | Chemical synthesis | Biological production |
| Stability | High (chemical stability) | Moderate (proteolytic degradation) |
| Immunogenicity | Low | Potential for immune response |
| Tissue Penetration | Better (smaller size) | Limited |
| Cost | Lower | Higher |
| Drug | Target | Indication | Development Stage | Status |
|---|---|---|---|---|
| RBM-007 | FGF2 (Fibroblast Growth Factor 2) | Wet AMD | Phase 2 | Active |
| RBM-007 | FGF2 | Diabetic Macular Edema | Preclinical | Research |
| RBM-007 | FGF2 | Ocular fibrosis | Research | Preclinical |
RBM-007 is an anti-FGF2 RNA aptamer being developed for multiple ocular diseases:
Mechanism of Action:
Wet Age-Related Macular Degeneration (AMD):
Diabetic Macular Edema (DME):
Ocular Fibrosis:
| Program | Target | Indication | Stage |
|---|---|---|---|
| CNS aptamer program | Various | Neurodegeneration | Discovery |
| Ocular new indications | Various | Dry eye, glaucoma | Discovery |
RIBOMIC operates primarily through a licensing model:
The company seeks partnerships with larger pharmaceutical companies:
| Company | Technology | Focus |
|---|---|---|
| Ionis Pharmaceuticals | ASO, RNAe | Various diseases |
| Alnylam Pharmaceuticals | siRNA | Various diseases |
| Dicerna Pharmaceuticals | GalNAc-siRNA | Various diseases |
| RIBOMIC | RNA aptamers | Ocular, CNS |
| Year | Event | Amount |
|---|---|---|
| 2012 | IPO | ¥500M |
| 2018 | Secondary offering | ¥800M |
| 2021 | Partnership funding | ¥200M |
Near-Term (2024-2025):
Long-Term (2025+):